In an open letter, Medicines for Europe, the European umbrella organisation of off-patent medicine manufacturers, expresses its concern about the impact of sharply increasing costs for the production, transport and distribution of medicines.
Cheap medicines in particular are at risk of falling victim to this.
"Incidentally, in Belgium our findings already show that about 10% of medicines are unavailable due to a lack of economic perspective. This mainly concerns old, low-priced medicines such as generic medicines. However, cheap medicines must remain available to patients. Let us all work together to prevent serious problems. I was therefore a co-signatory to the letter from Medicines for Europe," explains Joris Van Assche, managing director of Medaxes.